This study investigated the cholinesterase inhibitory properties of two FDA-approved drugs, propranolol and diltiazem, to evaluate their potential as symptomatic treatments for cognitive impairment, particularly in the context of AD and related dementias. This evidence concerns the gene BCHE and Alzheimer disease.